A Scottish consulting group on retainer to UPMC is under investigation by British authorities, reportedly for helping steer a government contract to a former UPMC joint venture in Pittsburgh.
There is no indication UPMC or the company, CombineMed, is a target of the investigation.
But as a result of the probe, the consultant, Americium Developments Ltd., has agreed to suspend work on the health care giant's behalf for the time being.
"We want to make sure everything is cleared," said Wendy Zellner, a UPMC spokeswoman.
UPMC continues to pay Americium a monthly retainer of 12,500 British pounds (about $18,100). And it still owns a minority stake in CombineMed's parent company, CombineNet, which is headquartered in the Strip District.
Metropolitan Police in London confirmed an investigation into fraud and corruption involving a group of government-run hospitals in England. They questioned three men last month but would not disclose any details.
However, a story in London's Sunday Times this week identified Americium as a target.
The newspaper reported that fraud investigators are examining Americium's role in helping CombineMed beat out other bidders for a contract with Hammersmith Hospital NHS Trust, which is now Imperial College Healthcare NHS Trust.
CombineMed's software helps companies find the best way to buy goods and services.
According to the newspaper report, at the same time Americium was being paid by UPMC and helping CombineMed structure its proposal, it was also working for the trust to handle the bidding process.
The trust said it could not discuss the situation because of the criminal investigation. Americium's partners could not be reached for comment.
Tony Bonidy, CombineNet's chief executive officer, said an Americium representative was on the five-member committee that reviewed the bids by 37 companies. CombineMed won the bid in 2007.
"They put them on this committee with full disclosure that Americium was doing work with UPMC in other areas and with us in this area, so everybody on this committee knew there could be a potential conflict there," Mr. Bonidy said.
"That's a business choice that Hammersmith had to make. As long as it's fully disclosed, everybody's aware of it."
Ms. Zellner said UPMC provided Hammersmith with a copy of its agreement with Americium, which included a prohibition on Americium making fees for "work that was brought from Hammersmith."
Mr. Bonidy confirmed that England's National Health Service is investigating Americium but said he does not know for what. He does not believe CombineMed or CombineNet is a target.
Ms. Zellner said UPMC understands that the focus is on "transactions involving Americium and Hammersmith. Beyond that I really don't know."
Last month, authorities visited CombineNet's London offices seeking information about Americium.
"They came to our offices, and so our management team over there was asked for materials and anything that would relate to Americium," Mr. Bonidy said yesterday. "Our guy asked a detective, 'Are we a subject of the investigation,' and he said, 'You may be a witness.' "
Americium has worked for UPMC since April 2007 to find business opportunities in Britain. As an outgrowth of that relationship, Americium assisted CombineMed.
Britain's huge nationalized health-care system was an attractive potential client for CombineMed. The National Health Service's Web site says it employs more than 1.5 million people -- behind only the Chinese army, Wal-Mart and India's train system.
Although CombineMed was awarded the contract, Mr. Bonidy said management at the trust changed and decided not to go forward with the deal.
"We never received one penny of revenue from Hammersmith," Mr. Bonidy said.
CombineMed paid Americium nothing more than expenses, Mr. Bonidy said.
UPMC's monthly payments to Americium did not include separate amounts for work done on CombineMed's behalf, according to Ms. Zellner.
In Oct. 2007, four CombineMed employees -- including Tom Finn, the company president at the time -- raised concerns about the bidding process.
They sent a two-page memo to UPMC's general counsel, Robert Cindrich, and the lawyer for CombineNet.
"UPMC and Americium orchestrated CombineMed's ability to dominate all aspects of what was supposed to be an unquestionably fair, closely regulated selection process," according to the memo, which was obtained by the Pittsburgh Post-Gazette.
"In short, we are very concerned that we, as individuals and as a company, have a potential legal problem, not only from a U.S. business practice perspective, but also from a UK anti-competitive stance."
Mr. Bonidy denied there was any bid-rigging, conflict of interest or attempt to give CombineMed a leg up on its competitors.
"It was a very open process. That's just the way their process works," Mr. Bonidy said. "Everybody had an opportunity to do the same thing."
The memo triggered several investigations, both internal and by outside law firms, that concluded there was no wrongdoing on the part of UPMC, CombineNet or CombineMed, said Mr. Bonidy and Ms. Zellner.
"They all did investigations. They all found no evidence of wrongdoing or any evidence that U.S. or U.K. laws were violated by anyone," Ms. Zellner said.
Mr. Finn was fired the day the memo was handed in. He could not be reached for comment. Two other employees who signed the memo were also terminated. The fourth remains working for CombineMed.
Mr. Bonidy said no one was fired for raising concerns. He said one employee had been gone for six months before the memo was written; another was let go as part of an overall restructuring; and the third was already on the chopping block before the memo was submitted.
One of the fired employees, Sean Martyn, a former project manager, called Mr. Bonidy's claims of no link between the memo and the firings "laughable."
Mr. Martyn, 28, said two weeks before the memo he was heavily involved with drafting staffing and travel plans for the project.
"The only thing that changed was the memo," Mr. Martyn said.


Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.